Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
07 nov. 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Pending Acquisition of Naltrexone Therapeutics Supported by Reports that Naltrexone Demonstrates Promising Long COVID Applications
21 oct. 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics,...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Update on Upcoming Launch of its Sponsored Psilocybin Trials at John Hopkins University
18 oct. 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) has provided an update on the launch of its psilocybin trials at John Hopkins University. LOVE...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Signing of Non-Binding LOI to Acquire 100% of Naltrexone Therapeutics Inc., a Pharmaceutical Technology Company with Significant IP Related to the Transdermal Delivery of FDA Approved Naltrexone
12 oct. 2022 06h21 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) has signed a non-binding Letter of Intent to acquire 100% of Naltrexone Therapeutics Inc., a...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Launch of its Love Pharma Online Shop, a Fully Integrated e-Commerce Platform Featuring its Proprietary Products, BLOOM and Auralief
22 sept. 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has launched its Love Pharma online shop, a...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Strategic Investment in Starton Therapeutics, a New Jersey Based Clinical Stage Biotechnology Company
08 sept. 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has made a strategic investment in Starton...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Shareholders’ Letter from CEO Zach Stadnyk
26 août 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Aug. 26, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has provided a shareholders’ update. Zach...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses LOVE Pharma’s Definitive Agreement to Acquire Doc Hygiene Pharmaceuticals Inc.
18 août 2022 06h00 HE | InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company, has entered into a definitive agreement to...